ArticleFuture oncology (London, England)2025

Real-world safety and efficacy of trastuzumab deruxtecan (T-DXd) in patients with HER2-positive/HER2-low metastatic breast cancer: a multicenter retrospective cohort study.

Elias Kotteas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.